unfortunately one research outcome is usually contradicted by another and in the case of longini , the research abstract i read several weeks ago supported the view that zanamivir showed greater efficacy against mutating strains than oseltamivir(tamiflu) and whilst gsk are planning to spend wads to build a vaccine fluarix, it seems rather imperious to state that it will be ready by 2008. they are not the only ones in the race to build a vaccine. and what about the newer neuraminidase inhibitors and ongoing other strains of flu that biota are targetting.
BTA Price at posting:
0.0¢ Sentiment: None Disclosure: Held
